Fig. 5From: Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapyComparison of the radiolabeling yield of (a) no-carrier-added 161Tb (SAFARI-1); b no-carrier-added 177Lu (ITG) and (c) carrier-added 177Lu (IDB) in combination with DOTA over time at different DOTA-to-nuclide molar ratiosBack to article page